May 23, 2014. A Comment about Variant Databases

Variant databases are an essential resource for both clinical and research genomics. Has the variant been reported previously in a patient and if so, what was their phenotype? They are used to exclude benign or common variants as pathogenetic, based on their high frequency in asymptomatic individuals. Many researchers curate variant databases of specific loci, regularly contribute known and new to public databases, and several companies release products aimed at compiling and visualizing this data. Determining the frequency and recurrence of variants can only be done through this compilation procedure.  Clinical labs maintain their own databases and regularly query public and commercial variant repositories to make sense of newly generated sequencing findings. Of course, it’s a lot easier to write up a variant if all one has to do is look it up in a database.

There is a fundamental problem with this approach: in a genome of 3.2 billion nucleotides, there are an infinite number of  possible mutations (single and oligo nucleotide changes on each chromosome). There is no database in existence that can catalog all of these effects, nor predict these effects based on prior knowledge of all of the mutation combinations. Only computational modeling of sequence variant effects can possibly provide a means of evaluting newly discovered mutations without explicit reference to a database of prior variants.  The approaches that Cytognomix has developed complement existing databases by confirming evidence of selection against predicted pathogenic variants (low allele frequencies), but more importantly, can predict deleterious effects when the mutation has not been observed previously.

 

May 19, 2014. Veridical wins best paper award at two conferences!

Coby Viner presented our F1000 paper on the Veridical algorithm and software at the 2014 Compute Ontario 1st Annual Research Conference (Waterloo, Ontario, May  7)  and at the 9th Annual Great Lakes Bioinformatics Conference (Cincinnati, Ohio, May 17). At these conferences, he received the Best Oral Presentation and Best Highlights Presentation award, respectively. This is an impressive achievement, and a testament to the originality and impact of the science.

Watch his presentation at the Compute Ontario conference:

May 12-13, 2014. Cytognomix exhibiting at OCE Discovery, Toronto

Cytognomix is exhibiting at the Ontario Centers of Excellence Annual Discovery Conference at the Toronto Convention Center. Ben Shirley will be representing the company and demonstrating some of our software products. We can be found at Booth 1711 (South Building 800 Level)  in the High Performance Computing Pavilion on the main exhibit floor.  We invite you to pick up a copy of our white paper and brochure.

May 12-13, 2014. Presentation at the 3rd Cancer Genome Atlas Scientific Symposium

Our abstract is being presented at The Cancer Genome Atlas’ 3rd Annual Scientific Symposium, at the Natcher Conference Center on the NIH Campus, Bethesda, MD. The presentation is:

Non-coding mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer. Dorman, S.N.1, Viner, C.2, Rogan, P.K1,2,3.
1Department of Biochemistry and 2Department of Computer Science, University of Western Ontario, London, ON, Canada, 3Cytognomix Inc., London, ON, Canada.

May 5, 2014. Presentation at the Cancer Genome Atlas 3rd Annual Symposium

Dr. Peter Rogan will be presenting a paper at the TCGA symposium at the  Natcher Conference Center on the NIH Campus, Bethesda, MD on May 12-13, 2014. The title and authors are:

Non-coding mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer.  Dorman, S.N.1, Viner, C.2, Rogan, P.K1,2,3.   1Department of Biochemistry and 2Department of Computer Science, University of Western Ontario, London, ON, Canada, 3Cytognomix Inc., London, ON, Canada.

The paper describes the use of Cytognomix’s Shannon splicing mutation pipeline and Veridical software to discover novel aberrant pathways in metastatic breast cancer.

Details about the meeting can be found at the conference website (link).